Becton Dickinson Forecasts Higher Sales From COVID-19 Diagnostic Testing Revenues

  • Becton Dickinson and Co BDX reported Q3 FY22 revenues of $4.6 billion, up 0.7% Y/Y (3.8% on a currency-neutral basis), better than the consensus of $4.47 billion.
  • Revenue was driven by base revenue growth of 6% as reported, 9.3% currency-neutral.
  • COVID-only testing revenues of $76 million declined from $300 million in the prior year.
  • Medical segment sales increased 4.7% Y/Y to $2.19 billion.
  • Life Sciences segment sales declined 8.7% Y/Y to $1.31 billion, reflecting the decline in COVID-only testing revenues.
  • Interventional segment revenues grew 5.5% Y/Y to $1.14 billion.
  • Operating income increased 9% Y/Y to $537 million.
  • Adjusted EPS of $2.66, up from $2.28 a year ago, topping the consensus of $2.50.
  • Guidance: BD expects FY22 sales of $18.75 - $18.83 billion compared to $18.5 - $18.7 billion expected previously and the consensus of $18.63 billion.
  • Becton Dickinson reaffirms approximately $500 million in COVID-19-only diagnostic testing revenues versus $450 million announced earlier.
  • It anticipates FY22 adjusted EPS of $11.28 - $11.35 compared to the prior guidance of $11.15 to $11.30 and the consensus of $11.24.
  • Price Action: BDX shares are up 1.85% at $249.46 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!